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Abstract
Healthy human prostate epithelial cells have the unique ability to produce and secrete large
amounts of citrate into the lumen of the prostate. Citrate is a Krebs cycle metabolite produced
in the condensation reaction between acetyl-CoA and oxaloacetate in the mitochondria of the
cell. Using 13C enriched substrates, the contributions of different metabolic pathways to this
production and secretion of citrate could be identified. In this work we present a probabilistic
model describing the production and secretion of citrate in the mitochondria of prostatic ep-
ithelial cells. We derived equations for the secretion probability of citrate and the contribution
of pyruvate dehydrogenase complex (PDC) versus the anaplerotic pyruvate carboxylase (PC)
pathways in supplying the Krebs cycle with carbons from pyruvate for the production of citrate.
This measure is independent of initial 13C-enrichment of the administered supplements and of
13C J-coupling patterns, making this method robust also if SNR is low. We propose that these
equations can be used to distinguish between citrate metabolism in healthy prostate tissue cells
and in malignant cells, or they can be used to follow changes in citrate metabolism during the
process towards malignancy.
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Introduction
Healthy prostate epithelial cells have the unique capability of secreting citrate in the ducts or
lumen of the prostate.1, where it can reach levels up to about 180 mM. Citrate accumulation
in the prostate is promoted by inhibition of the citrate converting enzyme m-aconitase through
zinc binding, which is taken up at relatively high levels in epithelial prostate cells.1–3 The char-
acteristic citrate accumulation is lost upon malignancy,4 and a decreased citrate signal in MR
spectroscopic images of the prostate is used as a biomarker for the presence of cancer.5–7 Prostate
cancer accounts for one in five cancers and is responsible for one in ten cancer related deaths
in men worldwide.8,9 Understanding metabolic reprogramming in malignant transformation may
help to better diagnose and treat prostate cancer.10–13 Citrate is the product of a condensation re-
action of oxaloacetate and acetyl-CoA catalyzed by citrate synthase as the first step of the Krebs
cycle. A major compound from which acetyl-CoA is derived is glucose, which is metabolized into
pyruvate by glycolysis and subsequently enters the the mitochondria where it is converted into
acetyl-CoA to enter the Krebs cycle. In this step two carbons enter the cycle, which is equal to
the carbon efflux as carbon dioxide, during one Krebs cycle turn. Because of citrate efflux into
the luminal space, removing six carbons from the cycle, anaplerotic contributions are required
to maintain the carbon pool of the Krebs cycle. One of these anaplerotic contributions can come
from pyruvate being converted into oxaloacetate by pyruvate carboxylase (PC). The influx of
this four-carbon metabolite can partly balance the efflux of six carbon citrate every Krebs cycle
turn.
The carbon flow for citrate production and secretion can be assessed by supplying prostate tis-
sue or cells in vivo or in vitro with 13C substrates and monitoring the fate of the 13C-labels by
13C MR spectroscopy or high resolution 13C NMR spectroscopy and looking at the specific 13C
labeling of metabolic products. In this way metabolic synthesis routes can be delineated and
quantified.
Multiple metabolic flux modeling studies have modeled Krebs cycle activity in different tissues
and cell types under different conditions in literature. This is done using (extensive) metabolic
networks involving fluxes between the metabolites in the network, like positional isotopomers14,
bonded cumomer analysis15 or elementary metabolite unit based methods16. For example, in
human melanoma cell line DB1, rat C6 glioma cells, H460 NSCLC cells, hepatocytes and brown
adipocytes and in isolated cardiac mitochondria relative fluxes of total TCA cycle activity VTCA
and exchange flux Vx of α-ketoglutarate with glutamate Vx are determined in vitro.
17–23 But
also in vivo in mouse and rat brain and heart24–28 and human brain.29–31 Overall, the different
contributions of pyruvate carboxylase activity, malic enzyme activity, glutaminolysis and other
cataplerotic and anaplerotic processes32 for different tissues and cells make it hard to generalize
Krebs cycle metabolism in such a way that it can be used to predict prostate metabolism. The
fast exchange between glutamate and α-ketoglutarate is one common element in these studies.
In prostate no such studies have been performed to date except for hyperpolarization studies
measuring (semi)quantitative fluxes in prostate.33 The unique citrate metabolism of the prostate
makes it hard to translate values found in these other studies to prostate metabolism.
The unique characteristic secretion of citrate by prostatic cells provides a six-carbon readout of
this Krebs cycle activity not used before as far as we know. A first practical approach to explore
this property would be in studies of prostate cells, but most prostatic epithelial cell lines lack
the capacity of citrate secretion. However, the prostate cancer metastasis cell line LNCaP has
been shown to have the capacity to secrete citrate and therefore can serve as a convenient model
system to evaluate if 13C labeling of secreted citrate can be explored as a readout for carbon
2
flow inside the cell.34–36 Using only simple ratios that can be extracted from MR spectroscopic
data or high resolution 13C NMR spectra we developed a simple probabilistic model for cellular
citrate production in this work. On one hand we determine an index for citrate production and
secretion versus Krebs cycle consumption and on the other hand an estimate of the balance be-
tween pyvuvate carboxylase (PC) and pyruvate dehydrogenase complex (PDC) activity in citrate
production.
Data collection
To follow citrate metabolism in healthy or malignant prostate epithelial tissue in vivo, or in
vitro in primary cell cultures or cell lines, [1,6-13C2]glucose or [3-
13C]pyruvate (both substrates
result in the same labeling patterns, as shown in subsequent sections) or [2,5-13C2]glucose or
[2-13C]pyruvate (again, both substrates result in the same labeling patterns) can be provided
for some time, long enough (e.g. 48h) to reach a steady state 13C labeling of citrate in the
extracellular fluid or incubation medium. After this the extracellular material could be collected
and analyzed by high resolution 13C NMR spectroscopy. Citrate resonances can be identified
and quantified (e.g. using j MRUI AMARES37–39) for further use. Using [3,4-13C2]glucose or
[1-13C]pyruvate would not result in labeling of citrate via the PDC pathway but only via the PC
pathway.
Quantitative model
The distribution of 13C carbons in citrate, as determined from NMR spectra, reflects on the
ratio of pyruvate going into the Krebs cycle via pyruvate carboxylase (as oxaloacetate) and
pyruvate dehydrogenase (as acetyl-CoA) on one hand and on the fraction of molecules leaving
the Krebs cycle every turn to be secreted into the lumen or incubation medium on the other
hand. Here we derive a probabilistic model describing prostatic citrate production depending
on a (constant) secretion probability c and on the fractions of carbons entering via acetyl-CoA
(fPDC) or oxaloacetate (fPC), with fPC + fPDC = 1. The 13C labeling at the six different
positions in citrate secreted and carbon dioxide produced at cycle turn n is described by
−→
C (n).
−→
C (n) =

C1(n)
C2(n)
C3(n)
C4(n)
C5(n)
C6(n)
CO2(n)

c(1− c)n (1)
Since every Krebs cycle turn a fraction c of citrate leaves the cycle and fraction (1− c) remains
in the cycle a factor c(1− c)n is included. For example, if at n = 3 citrate molecules are secreted
with 20% label on C2, 10% on C4 and 5% on C5 and C6, and 3% label is lost in carbon dioxide,
3
this would be:
−→
C (n) =

0
0.2
0
0.1
0.05
0.05
0.03

c(1− c)3 (2)
Equations for this are derived further on in this paper.
Fate of 13C labels in the Krebs cycle
When a 13C label enters the Krebs cycle it can end up at different positions in citrate (see Figure
1). If a label continues down the Krebs cycle it can eventually end up in citrate again, but now
at a different position, or even distributed equally over two citrate carbon positions. This is
because succinate and fumarate are symmetrical intermediates in the Krebs cycle resulting in
indistinguishable labelings of C1 and C4 or C2 and C3 in succinate and fumarate. Eventually
this leads to an equal distribution of 13C labels at two carbon positions in citrate. The position
of 13C labels at citrate carbons C1-C6 and oxaloacetate (OAA) at cycle turn n+ 1 versus n are
shown in Table 1.
Citr(n) ⇒ OAA(n) ⇒ Citr(n+ 1)
C1 ⇒ 12C1 + 12C4 ⇒ 12C5 + 12C6
C2 ⇒ 12C2 + 12C3 ⇒ 12C3 + 12C4
C3 ⇒ 12C2 + 12C3 ⇒ 12C3 + 12C4
C4 ⇒ 12C1 + 12C4 ⇒ 12C5 + 12C6
C5 ⇒ CO2
C6 ⇒ CO2
Table 1: Shifting of carbons of citrate during the Krebs cycle. Shown are citrate (Citr) at Krebs
cycle turn n, oxaloacetate (OAA) at cycle turn n and citrate at cycle turn n + 1. Cycle turn n
starts at the secretion of citrate and ends upon formation of new citrate in the subsequent cycle
turn.
First labeling of citrate (n = 0)
The (13C) carbons of pyruvate can enter the Krebs cycle via the pyruvate carboxylase (PC) and
the pyruvate dehydrogenase complex (PDC) route. We define Krebs cycle turn n as the number
of full Krebs cycle turns completed before secretion of citrate from the Krebs cycle. This means
that if citrate is secreted right after it is labeled, this is Krebs cycle turn n = 0. This is the
only cycle turn where 13C carbons enter the Krebs cycle via PC because the oxaloacetate during
the next Krebs cycle turns (n > 0) originates from the citrate in the previous Krebs cycle turn
4
Figure 1: Schematic representation of the fate of 13C carbons entering the Krebs cycle during
subsequent cycle turns. A.) The distribution of 13C labels originating from [1,6-13C2]glucose or
[3-13C]pyruvate. (C) Idem for [2,5-13C2]glucose or [2-
13C]pyruvate. Pyruvate carbons converted
to oxaloacetate by pyruvate carboxylase (PC) are indicated by blue circles and those converted
into acetyl-CoA by pyruvate dehydrogenase complex (PDC) by red circles. In this figure the
carbon numbers in each compound are indicated and for simplicity mitochondrial and cellular
export of citrate is omitted. In this figure no new 13C label is flowing into the Krebs cycle during
the subsequent cycle turns, this however is taken into account in the sections below.
that is not secreted. On the other hand, this oxaloacetate undergoes a condensation reaction
with a 13C labeled acetyl-CoA every Krebs cycle turn, so carbons enter the Krebs cycle via PDC
every cycle turn. The first labeled citrate (at n = 0) produced can be different depending on
the labeling of pyruvate (or acetyl-CoA) substrates. For [1,6-13C2]glucose or [3-
13C]pyruvate the
route of labeling of citrate is shown in Figure 2. 13C labeled oxaloacetate (OAA) and 13C labeled
acetyl-CoA are formed and can together with unlabeled oxaloacetate or acetyl-CoA undergo a
condensation reaction to produce unlabeled, single- or double 13C labeled citrate. Resulting in
citrate labeled at C2 (PDC) and/or C4 (PC) respectively at n = 0. If [2,5-13C2]glucose or [2-
13C]pyruvate is used as substrate the scheme in Figure 3 can be produced. Resulting in citrate
labeling at C1 (PDC) and/or C3 (PC) respectively at n = 0. Note here that if P and A were to
be fractions of 13C label ending up in oxaloacetate via PC or acetyl-CoA via PDC respectively,
the resulting distribution of 13C label over the two citrate positions that are possibily labeled
at n = 0 is equal to P at one position and A at the other. For the [1,6-13C2]glucose or [3-
13C]pyruvate experiment this would be A C2 label and P C4 label. For the 13C [2,5-13C2]glucose
or [2-13C]pyruvate experiment this results in A label at the C1 position and P label at the C3
position.
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[1,6-13C2]Glc [3-
13C]Pyr
OxaAc
[2-13C]Ac-CoA
[2-13C]Citr
[2,4-13C2]Citr
PDC
[3-13C]OxAc
[4-13C]Citr
PC
Ac-CoA
Glycolysis Citrate
synthase
Figure 2: For n = 0 13C labels originating from [1,6-13C2]glucose or [3-
13C]pyruvate end up in
oxaloacetate (at C2) via pyruvate carboxylase or via acetyl-CoA (at C1) via pyruvate dehydro-
genase complex before ending up in citrate after the condensation reaction of acetyl-CoA and
oxaloacetate. This can result in unlabeled (not shown), single labeled and double labeled citrate.
With Glc = glucose, Pyr = pyruvate.
[2,5-13C2]Glc [2-
13C]Pyr
OxaAc
[1-13C]Ac-CoA
[1-13C]Citr
[1,3-13C2]Citr
PDC
[2-13C]OxAc
[3-13C]Citr
PC
Ac-CoA
Glycolysis Citrate
synthase
Figure 3: For n = 0 13C labels originating from [2,5-13C2]glucose or [2-
13C]pyruvate can either
end up in oxaloacetate (at C2) via pyruvate carboxylase or in acetyl-CoA (at C1) via pyruvate
dehydrogenase complex before it ends up in citrate after the condensation reaction of acetyl-CoA
and oxaloacetate. This can result in unlabeled (not shown), single labeled and double labeled
citrate. With Glc = glucose, Pyr = pyruvate.
Pyruvate carboxylase vs pyruvate dehydrogenase complex
To determine the fractional contributions of the PC and PDC routes to the final citrate pool in
the luminal fluid or incubation medium it is essential to realize that depending on how many
Krebs cycle turns a 13C label completes before being secreted, the contribution is different. Let’s
start with fraction A 13C labels getting into citrate via PDC and fraction P 13C labels getting
into citrate via PC. Subsequently fraction c of the citrate will be secreted (we define this as Krebs
cycle turn n = 0) and fraction (1− c) continues in the Krebs cycle. Now (1− c) carbon skeletons
will be labeled again upon condensation of the carbon skeleton (oxaloacetate) with (1 − c) 13C
acetyl-CoA forming (1−c) citrate. Of this citrate again fraction c is secreted (n = 1) and fraction
(1 − c) continues down the Krebs cycle and the process repeats itself. This is summarized in
Figure 5. Pyruvate carboxylase only contributes to the 13C labeling of the citrate pool in the
luminal fluid or incubation medium at n = 0 and pyruvate dehydrogenase complex contributes
to the citrate pool during all Krebs cycle turns. In general, during cycle turn n > 0 there will
be A(1 − c)n labels entering the cycle and Ac(1 − c)n citrate molecules will be secreted. Only
at n = 0 there will be A + P labels entering the cycle and c(A + P ) citrate molecules will be
secreted. The sum of all fractions of 13C labels entering the Krebs cycle has to be equal to
fPC + fPDC = 1 and since the only time labels originating from the PC route can enter the
6
cycle is at turn n = 0, we can easily see fraction fPC is equal to the fraction P described above.
Fraction fPDC has to be equal to the sum of fractions of 13C labels entering via acetyl-CoA,
which comes down to the following sum:
fPDC = A
n=∞∑
n=0
(1− c)n = A
c
(3)
This means that if at n = 0 fraction fPC of pyruvate 13C labels enter the cycle via the PC route
and fraction A = cfPDC enters the cycle via the PDC route, summed over all possible Krebs
cycle turns a total of fPC + cf
PDC
c = f
PC + fPDC = 1 13C labels enter the Krebs cycle (Figure
4).
Figure 4: Fractions pyruvate carboxylase fPC and pyruvate dehydrogenase complex fPDC versus
secretion probability c. The sum of fPC and fPDC is equal to 1. The initial fraction (at
n = 0) of carbon entering the Krebs cycle via PDC depends on the value of c, since fPDC =
fPDC0
n=∞∑
n=0
(1− c)n = fPDC0 c . Next to this, fPDC0 ≤ fPC , since for every oxaloacetate labeled via
the PC route, there is an acetyl-CoA needed (labeled by PDC) at n = 0, making the blue line
start at PC=cPDC.
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13C-Pyr
A(1− c)∞ acetyl-CoA
n
=∞ etc
A(1− c)2 13C acetyl-CoAn = 2
A(1− c) 13C acetyl-CoA
n = 1
A 13C acetyl-CoA
n =
0
P 13C oxaloacetate
n
=
0
fPDC
fPC
= P +A
n=∞∑
n=0
(1− c)n = P + A
c
= 1⇒
{
fPC = P
fPDC = A
c
Figure 5: Fate of 13C labels of pyruvate entering the Krebs cycle and ending up in citrate.
Fraction P = fPC enters via the pyruvate carboxylase pathway as oxaloacetate (only at n = 0),
fraction fPDC = Ac flows into the Krebs cycle via the pyruvate dehydrogenase complex pathway
as acetyl-CoA.
Average number of completed Krebs cycle turns before citrate secretion
The average number of Krebs cycle turns before secretion of citrate (This is not the same as the
average number of Krebs cycle turns a 13C carbon completes, see Appendices for the average
number of cycle turns a 13C carbon completes) depends on the secretion probability c. To
calculate this average number of cycle turns < n > the sum can be calculated of the fractions
secreted every cycle c(1− c)n multiplied with their corresponding Krebs cycle turn indices n.
< n >= c
n=∞∑
n=0
n(1− c)n = 1− c
c
(4)
The average number of cycle turns is equal to the ratio of the fraction of molecules that stay in
the Krebs cycle (1− c) over the fraction of molecules that are secreted c.
Effect of 13C enrichment
We assume that the pool of 13C pyruvate, present during the infusion or incubation period, is
much larger than the Krebs cycle pool of 13C carbons. So we assume the enrichment of this pool
to be constant as well. Until now we assumed all pyruvate or glucose to be 13C labeled. This
probably doesn’t reflect the true situation so introducing a enrichment factor in the equations
could correct for this. Suppose only fraction  of pyruvate is 13C labeled, then fractions cfPDC
(via pyruvate dehydrogenase complex) and fPC (via pyruvate carboxylase) of 13C carbons will
enter the Krebs cycle at n = 0, cfPDC(1− c) at n = 1, cfPDC(1− c)2 at n = 2 and so forth.
−−→
13Cdistr = 
n=∞∑
n=0
−→
C (n) (5)
This means the contributions of the individual cycle turns to the sum (final 13C distribution)
are all multiplied by  and we can assume a constant enrichment factor of  = 1 when deriving
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equations for the 13C distribution over the citrate carbons and carbon dioxide for both the [1,6-
13C2]glucose or [3-
13C]pyruvate and [2,5-13C2]glucose or [2-
13C]pyruvate experiments in the next
sections. This only holds if the value of  is not time-dependent. If high enough concentrations or
constant inflow of 13C substrate is provided, we can safely assume this to be true during most of
the infusion or incubation period. This means there is no change in relative 13C distribution over
the different citrate carbons and the citrate 13C carbon integrals we use later on are unaffected,
as are the secretion probability c and pyruvate carboxylase fraction fPC we derive later on.
Providing [1,6-13C2]glucose or [3-
13C]pyruvate to tissue/cells
To see how glucose or pyruvate contribute to the production and secretion of citrate, one could
provide [1,6-13C2]glucose or [3-
13C]pyruvate to the epithelial cells or tissue for a longer period of
time (e.g. 48h). Glucose is taken up by the cells and converted into pyruvate during glycolysis. In
case of [1,6-13C2]glucose the
13C label will be located at the C3 position of pyruvate as shown in
section ”First labeling of citrate (n = 0)”. Subsequently this label can end up at the oxaloacetate
C3 position or acetyl-CoA C2 position. The first will result in labeling at C2 of citrate, the latter
at C4. So, the 13C carbon distribution in citrate at cycle turn n = 0 will look like (neglecting
carbon dioxide for now):
−→
C (n = 0) =

0
cfPDC
0
fPC
0
0
 c (6)
After one turn the distribution will have shifted according to Table 1 and more label is added at
the C2 position via PDC.
−→
C (n = 1) =

0
cfPDC
c
2f
PDC
c
2f
PDC
1
2f
PC
1
2f
PC

c(1− c) (7)
We assume here that all the label being added at C2 is 13C labeled. We discussed this assumption
in section ”Effect of 13C enrichment”. For cycle turns n ≥ 2 the distribution at cycle n can be
written in a more general way as:
−→
C (n ≥ 2) =

0
1
i=n∑
i=1
1
2i
i=n∑
i=1
1
2i
i=n∑
i=2
1
2i
i=n∑
i=2
1
2i

fPDCc2(1− c)n (8)
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We would like to know the distribution of 13C labels over the six citrate carbons in the extra-
cellular fluid or incubation medium when the citrate 13C distribution is in a steady state. This
can be calculated by summing the contributions of citrate secreted during each individual Krebs
cycle turn n to the total secreted citrate:
−−→
13C1,6-glcdistr =
n=∞∑
n=0
−→
C (n) =

0
cfPDC
n=∞∑
n=0
(1− c)n
cfPDC
n=∞∑
n=1
i=n∑
i=1
(1−c)n
2i
cfPDC
n=∞∑
n=1
i=n∑
i=1
(1−c)n
2i + f
PC
cfPDC
n=∞∑
n=2
i=n∑
i=2
(1−c)n
2i +
(1−c)
2 f
PC
cfPDC
n=∞∑
n=2
i=n∑
i=2
(1−c)n
2i +
(1−c)
2 f
PC

c =

0
fPDC
1−c
1+cf
PDC
1−c
1+cf
PDC + fPC
1−c
2
(
1−c
1+cf
PDC + fPC
)
1−c
2
(
1−c
1+cf
PDC + fPC
)

c
(9)
These equations give the 13C label distribution over the six carbons in secreted citrate. This
distribution only depends on secretion probability c and the fraction of carbon entering the Krebs
cycle via the pyruvate carboxylase route, fPC , since fPDC = 1− fPC . The 13C distribution for
fPC = 0.2 is plotted against c in figure 6.
Figure 6: 13C distribution over the six citrate carbons versus secretion probability c after pro-
viding [1,6-13C2]glucose or [3-
13C]pyruvate to prostate epithelial tissue or cells. Assuming a
pyruvate carboxylase fraction equal to fPC = 0.2.
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Providing [2,5-13C2]glucose or [2-
13C]pyruvate to tissue/cells
To determine how differently labeled glucose or pyruvate contribute to the production of citrate,
[2,5-13C2]glucose or [2-
13C]pyruvate could be provided to epithelial tissue or prostate epithelial
cells for a long enough period of time (e.g. 48h). Pyruvate is taken up by the cells and in
this case the 13C label will be located at a different pyruvate carbon position compared to the
experiments in section ”Providing [1,6-13C2]glucose or [3-
13C]pyruvate to tissue/cells”. When
this 13C label enters the Krebs cycle, it can end up at the oxaloacetate C2 position, via pyruvate
carboxylase, or at the acetyl-CoA C1 position via pyruvate dehydrogenase complex. The first
will result in a first labeling at C3 of citrate, the latter at C1. So, the 13C carbon distribution
in citrate at cycle turn n = 0 will look like (again, neglecting carbon dioxide for now):
−→
C (n = 0) =

cfPDC
0
fPC
0
0
0
 c (10)
After one turn this distribution will have shifted again like in section ”Providing [1,6-13C2]glucose
or [3-13C]pyruvate to tissue/cells” (see also Table 1) and new label is added at the C1 (via PDC)
position of citrate every cycle turn.
−→
C (n = 1) =

cfPDC
0
1
2f
PC
1
2f
PC
c
2f
PDC
c
2f
PDC

c(1− c) (11)
From cycle turn n ≥ 2 on the distribution at cycle turn n can be written in a more general way
as
−→
C (n ≥ 2) =

cfPDC
0
1
2n f
PC
1
2n f
PC
1
2n f
PC + c2f
PDC
1
2n f
PC + c2f
PDC

c(1− c)n (12)
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The distribution of 13C carbons over the carbons in the secreted citrate can be calculated again
by calculating the sum of the contributions of all individual Krebs cycle turns n
−−→
13Cglc-2,5distr =
n=∞∑
n=0
−→
C (n) =

cfPDC
n=∞∑
n=0
(1− c)n
0
fPC
n=∞∑
n=0
(
1−c
2
)n
fPC
n=∞∑
n=1
(
1−c
2
)n
c
2f
PDC
n=∞∑
n=1
(1− c)n + fPC
n=∞∑
n=2
(
1−c
2
)n
c
2f
PDC
n=∞∑
n=1
(1− c)n + fPC
n=∞∑
n=2
(
1−c
2
)n

c
=

fPDC
0
2
1+cf
PC
1−c
1+cf
PC
1−c
2
(
1−c
1+cf
PC + fPDC
)
1−c
2
(
1−c
1+cf
PC + fPDC
)

c
(13)
These equations give the steady state 13C label distribution in citrate in the extracellular space
or incubation medium after supplementation with [2,5-13C2]glucose or [2-
13C]pyruvate. The
distribution depends on secretion probability c and on the fractions of 13C carbon entering the
Krebs cycle via the pyruvate carboxylase route, fPC and pyruvate dehydrogenase complex fPDC
(with fPDC = 1 − fPC). The distribution of 13C carbons for fPC = 0.2) is shown in Figure 7
plotted against secretion probability c.
CO2 production
Next to citrate production and secretion we also have to take into account how much carbon
dioxide is produced every cycle and sum these contributions to see how much 13C labels are lost
as carbon dioxide. During a Krebs cycle turn one six-carbon molecule of citrate is converted
into a four-carbon metabolite oxaloacetate and two carbons are lost as carbon dioxide. The first
carbon is lost during the conversion of isocitrate into α-ketoglutarate and the second carbon is
lost in the next step of the Krebs cycle during the conversion of α-ketoglutarate into succinyl-
CoA. The first originates from the C6 carbon in citrate and the latter originates from citrate C5.
So, the carbon dioxide production at cycle turn n is equal to the sum of citrate carbons C5 and
C6 at this cycle turn n times (1 − c) instead of times c since the production of carbon dioxide
during cycle n takes place after the secretion of (1 − c)n citrate. In other words, only the 13C
carbons at C5 and C6, which are not secreted (fraction (1 − c)n) at cycle n, are lost as carbon
dioxide. This means we could calculate the carbon dioxide production at cycle turn n by adding
the 13C distribution at C5 and C6 and multiply this by 1−cc . Because the
13C distribution at C5
and C6 is equal, this could be written as:
−−→
CO2(n) = 2
1− c
c
−→
C5(n) (14)
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Figure 7: 13C distribution over the six citrate carbons versus secretion probability c after pro-
viding [2,5-13C2]glucose or [2-
13C]pyruvate to prostate epithelial tissue or cells. Assuming a
pyruvate carboxylase fraction equal to fPC = 0.2.
To calculate the resulting CO2 produced over time the contributions of all cycle turns have to
be summed.
−−→
CO2distr =
n=∞∑
n=0
−−→
CO2(n) = 2
1− c
c
n=∞∑
n=0
−→
C5(n) (15)
Another way of calculating this is by evaluating the individual contributions for every cycle turn−−→
CO2(n) to the total CO2 for different values of n, like we did before for the carbons in citrate.
For [1,6-13C2]glucose or [3-
13C]pyruvate this looks like:
−−→
CO2(n = 0) = 0 (16)
−−→
CO2(n = 1) = 0 (17)
−−→
CO2(n = 2) = f
PC(1− c)2 (18)
−−→
CO2(n ≥ 3) = cfPDC
i=n−2∑
i=1
1
2i
(1− c)n (19)
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This means we can calculate the total amount of CO2 by summing these contributions:
−−→
CO2distr =f
PC(1− c)2 + fPDCc
n=∞∑
n=3
i=n−2∑
i=1
1
2i
(1− c)n (20)
=(1− c)3fPDC − c(1− c)
3
1 + c
fPDC + (1− c)2fPC (21)
=
2(1− c)
c
[
1− c
2
(
1− c
1 + c
fPDC + fPC
)
c
]
(22)
In the last step the equation has been rewritten to show that the total CO2 indeed is equal to the
final 13C distribution at citrate C5 (or C6) times 2 1−cc . Since the total
13C entering the Krebs
cycle in our model is equal to fPC + fPDC = 1 and we only take citrate production/secretion
and CO2 into account in our model the total
13C found in citrate and CO2 should also add up
to 1. If we take the sum of the label distribution of the carbons of citrate and add the amount
of CO2 we should end up with f
PC + fPDC = 1. For [1,6-13C2]glucose or [3-
13C]pyruvate this
looks like:
−−→
Citrglc-1,6,sumextr.cell. = cf
PDC
(
1 +
1− c
1 + c
(
3− c+ (1− c)
2
c
))
+ fPC
(
(2− c)c+ (1− c)2) (23)
=
1
c
cfPDC + fPC (24)
= fPDC + fPC = 1 (25)
We can repeat this for [2,5-13C2]glucose or [2-
13C]pyruvate as well to see what comes out. First
we have a look at the value of
−−→
CO2(n) for different values of n, like we did before for the carbons
in citrate:
−−→
CO2(n = 0) = 0 (26)
−−→
CO2(n = 1) = 0 (27)
−−→
CO2(n = 2) = (1− c)2fPDC (28)
−−→
CO2(n = 3) = (f
PDC +
1
2
fPC)(1− c)3 (29)
−−→
CO2(n = 4) = (f
PDC +
1
4
fPC)(1− c)4 (30)
−−→
CO2(n ≥ 3) = (fPDC + 1
2n−2
fPC)(1− c)n (31)
Now we can again calculate the total amount of CO2 produced during the experiment by summing
over n:
−−→
CO2distr =f
PDCc
n=∞∑
n=2
(1− c)n + fPC
n=∞∑
n=3
(1− c)n
2n−2
(32)
=(1− c)2fPDC + (1− c)
3
1 + c
fPC (33)
=2
(1− c)
c
(
1− c
2
(
1− c
1 + c
fPC + fPDC
)
c
)
(34)
So again the CO2 production is equal to the sum of carbon labeling at citrate C5 and C6 times
the factor 1−cc . The total amount of carbon entering the system has to be equal to the amount
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of carbon ending up in either citrate carbons or CO2. If we take the sum of the labeling in the
carbons of citrate and add the amount of CO2 we should again end up with f
PC + fPDC = 1.
For [2,5-13C2]glucose or [2-
13C]pyruvate this looks like:
−−→
Citrglc-2,5,sumextr.cell. =
1− c
1 + c
(
2c− c2 + 2c
1− c + (1− c)
2
)
fPC + (2c− c2 + (1− c)2)fPDC (35)
= fPC + fPDC = 1 (36)
So the total of 13C label entering the Krebs cycle is equal to the total 13C label we find after the
experiment in citrate (extracellular or in the incubation medium) and in CO2.
PDC versus PC contribution to citrate 13C-labeling
The equations we found for the 13C distribution can also easily be split in separate contributions
of the PC and PDC route for both the [1,6-13C2]glucose or [3-
13C]pyruvate and [2,5-13C2]glucose
or [2-13C]pyruvate experiments. Doing this for [1,6-13C2]glucose or [3-
13C]pyruvate:
−−→
13Cglc-1,6distr =

0
fPDC
1−c
1+cf
PDC
1−c
1+cf
PDC + fPC
1−c
2
(
1−c
1+cf
PDC + fPC
)
1−c
2
(
1−c
1+cf
PDC + fPC
)
(1−c)2
c
(
1−c
1+cf
PDC + fPC
)

c =

0
1
1−c
1+c
1−c
1+c
(1−c)2
2(1+c)
(1−c)2
2(1+c)
(1−c)3
c(1+c)

cfPDC +

0
0
0
1
1−c
2
1−c
2
(1−c)2
c

cfPC (37)
And for [2,5-13C2]glucose or [2-
13C]pyruvate we can do the same and end up with the following
equations:
−−→
13Cglc-2,5distr =

fPDC
0
2
1+cf
PC
1−c
1+cf
PC
1−c
2
(
1−c
1+cf
PC + fPDC
)
1−c
2
(
1−c
1+cf
PC + fPDC
)
(1−c)2
c
(
1−c
1+cf
PC + fPDC
)

c =

1
0
0
0
1−c
2
1−c
2
(1−c)2
c

cfPDC +

0
0
2
1+c
1−c
1+c
(1−c)2
2(1+c)
(1−c)2
2(1+c)
(1−c)3
c(1+c)

cfPC (38)
Overestimation of secretion
If a part of the molecules are extracted from the Krebs cycle for other metabolic processes, the
fraction of molecules remaining in the cycle will be smaller than (1− c). Let’s define a ’leakage
factor’ 1 − d which includes both the molecules lost to citrate secretion and to other metabolic
processes involving for example aspartate and glutamate. So d ≥ c or 1− d ≤ 1− c. Now we can
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recalculate the equations derived earlier, first for [1,6-13C2]glucose:
−−→
13Cglc-1,6distr,leak =
n=∞∑
n=0
(
1− d
1− c
)n−→
C (n) =

0
dfPDC
n=∞∑
n=0
(1− d)n
dfPDC
n=∞∑
n=1
i=n∑
i=1
(1−d)n
2i
dfPDC
n=∞∑
n=1
i=n∑
i=1
(1−d)n
2i + f
PC
dfPDC
n=∞∑
n=2
i=n∑
i=2
(1−d)n
2i +
(1−d)
2 f
PC
dfPDC
n=∞∑
n=2
i=n∑
i=2
(1−d)n
2i +
(1−d)
2 f
PC

c
=

0
fPDC
1−d
1+df
PDC
1−d
1+df
PDC + fPC
1−d
2
(
1−d
1+df
PDC + fPC
)
1−d
2
(
1−d
1+df
PDC + fPC
)

c
(39)
For [2,5-13C2]glucose or [2-
13C]pyruvate we can do the same:
−−→
13Cglc-2,5distr,leak =
n=∞∑
n=0
(
1− d
1− c
)n−→
C (n) =

dfPDC
n=∞∑
n=0
(1− d)n
0
fPC
n=∞∑
n=0
(
1−d
2
)n
fPC
n=∞∑
n=1
(
1−d
2
)n
d
2f
PDC
n=∞∑
n=1
(1− d)n + fPC
n=∞∑
n=2
(
1−d
2
)n
d
2f
PDC
n=∞∑
n=1
(1− d)n + fPC
n=∞∑
n=2
(
1−d
2
)n

c
=

fPDC
0
2
1+df
PC
1−d
1+df
PC
1−d
2
(
1−d
1+df
PC + fPDC
)
1−d
2
(
1−d
1+df
PC + fPDC
)

c
(40)
The resulting equations are similar to the equations obtained earlier, but c is replaced by d
everywhere and then all equations are multiplied by cd .
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Calculation of secretion probability c and PC fraction fPC
Experimental ratios
Looking at the equations obtained in sections ”Providing [2,5-13C2]glucose or [2-
13C]pyruvate to
tissue/cells” and ”Providing [1,6-13C2]glucose or [3-
13C]pyruvate to tissue/cells” (also summa-
rized in Table 2) we can define experimental ratios of 13C citrate integrals which can be easily
obtained from 13C MR spectra. Since citrate C2 and C4 on one hand and C1 and C5 on the other
are chemically equivalent, we only have to consider ratios of C1/5, C2/4, C3 and C6. We suggest
the following experimental ratios of fitted 13C citrate integrals to be used because they contain
the largest integrals for most of the values of c: R1 for the [1,6-
13C2]glucose or [3-
13C]pyruvate
experiments and R2 for the [2,5-
13C2]glucose or [2-
13C]pyruvate experiments.
R1 =
C2 + C4 − C3
C2 + C4
(41)
R2 =
C1 + C5
C3
(42)
These ratios can than be used as experimental input values for the quantitative model we de-
rived in this work describing citrate production and secretion in prostate epithelial tissue or cell
lines. After providing prostate tissue or cells with either [1,6-13C2]glucose or [3-
13C]pyruvate
or [2,5-13C2]glucose or [2-
13C]pyruvate, the extracellular material, being extracellular fluid or
incubation medium, can be analyzed using 13C NMR spectroscopy. After identification of the
citrate resonance peaks two citrate carbon resonance integral ratios can be calculated for the
different 13C labeled citrate carbons. These are then used to calculate secretion probability c
and pyruvate carboxylase contribution fPC
Secretion probability
With ratio R1 (from the [1,6-
13C2]glucose or [3-
13C]pyruvate experiments) and ratio R2 (from
the [2,5-13C2]glucose or [2-
13C]pyruvate experiments) we can calculate the secretion probability.
First we rewrite the equation for R1:
R1 =
C2/4 − C3
C2/4
=
C2 + C4 − C3
C2 + C4
=
fPDC + 1−c1+cf
PDC + fPC − 1−c1+cfPDC
fPDC + 1−c1+cf
PDC + fPC
(43)
If for example c = 0.3 and fPC = 0.2, than R1 would be R1 ≈ 0.7. This equation can also be
rewritten as an expression for fPDC as a function of c and R1:
fPDC =
1−R1
R1
1 + c
1− c (44)
From [2,5-13C2]glucose or [2-
13C]pyruvate experiments we can calculate ratio R2:
R2 =
C1/5
C3
=
C1 + C5
C3
=
fPDC + 1−c2
(
1−c
1+cf
PC + fPDC
)
2
1+cf
PC
(45)
=
1−R1
R1
1+c
1−c +
1−c
2
(
1−c
1+c
(
1− 1−R1R1 1+c1−c
)
+ 1−R1R1
1+c
1−c
)
2
1+c
(
1− 1−R1R1 1+c1−c
) (46)
17
In which we inserted the equations for fPDC derived above. If for example c = 0.3 and fPC = 0.2,
than R2 would be R1 ≈ 3.6. This can be simplified to solve for c by rewriting this into a cubic
equation:
(2−R1)c3 − (R1 + 2)c2 + (9R1 − 4R2 − 6)c+ (8R1R2 +R1 − 4R2 − 2) = 0 (47)
After substituting experimentally found values for R1 and R2 in this cubic equations, we can
solve for c. We can do this for the example values for R1 and R2 (for c = 0.3 and f
PC = 0.2).
1.3c3 − 2.7c2 − 14.3c+ 4.5 = 0 (48)
Solving the cubic equations gives us c = 0.3 again.
Fraction fPC vs fPDC
Now, using the expression we derived earlier we can calculate fraction fPDC (and at the same
time fPC):
fPDC =
1−R1
R1
1 + c
1− c (49)
fPC =1− fPDC (50)
Probabily most of the 13C labels do enter the Krebs cycle via the PDC route and a smaller
fraction of the 13C labels flow into the Krebs cycle of the anaplerotic pathway via pyruvate
carboxylase.
Using the values for c and fPC we can calculate the total integrals of the citrate and carbon
dioxide carbons according to our model (Figure 8 and 9). Looking at the predicted 13C integrals
for the different citrate carbons assuming c = 0.3 and fPC = 0.2, we can see that indeed C2/4 and
C3 in the [1,6-13C2]glucose or [3-
13C]pyruvate experiment is the best choice taking into account
SNR, but for the [2,5-13C2]glucose or [2-
13C]pyruvate experiment the C1/5 and C6 signals would
have been best to evaluate. However, often the peak of citrate C6 overlaps with another peak in
the 13C spectrum (e.g. pyroglutamate), making C3 the best choice.
Average number of Krebs cycle turns
Using equation 4 derived in section ”Average number of completed Krebs cycle turns before citrate
secretion” the average number of Krebs cycle turns that are completed before secretion of citrate
can be calculated:
< n >=
n=∞∑
n=0
nc(1− c)n = 1− c
c
(51)
Pyruvate carboxylase fraction dependence on secretion probability
In section ”Fraction fPC vs fPDC” an expression was derived for fraction fPDC (and for fPC
using fPC = 1− fPDC) depending on c and R1. We can derive a similar equation for fPC only
depending on c and R2.
R2 =
C1/5
C3
=
C1 + C5
C3
=
fPDC + 1−c2
(
1−c
1+cf
PC + fPDC
)
2
1+cf
PC
(52)
fPC =
1
2
4− (1− c)2
1− (1− c)2 + (2R2 + 1) (53)
Using this equation we can plot c versus fPC for different values of R1 and R2 (Figure 10).;
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Figure 8: Relative 13C-NMR integrals of the six citrate carbons and carbon dioxide for different
values of fPC (A-C), with c = 0.3 and different values of c (D-F) with fPC = 0.2 after providing
[1,6-13C2]glucose or [3-
13C]pyruvate to prostate epithelial tissue or cells. Carbons C1 and C5,
and C2 and C4 have the same chemical shift and their integrals are therefore summed here.
Error propagation
The experimental ratios found in the 13C experiments of course are subject to error due to
SNR limitations of the spectra and this has it’s effect on the values for c and fPC that we
calculated. Assuming a standard deviation of 1%, 2% or 5% of the largest integral in the ratios
for all components in the ratio (in a way similar to relative noise levels of 1%, 2% and 5%) and
calculate the error propagation and what this would mean for the assumed values of c = 0.3
and fPC = 0.2 we were able to define error bounds for c and fPC (Figure 11). A large spread
in possible values for c is seen at increasing error, while a more moderate spread is observed in
values for fPC .
Effect of efflux of other metabolites
Secretion probability with efflux of other metabolites
In the previous sections we neglected the contributions of other metabolic pathways (both cat-
aplerotic and anaplerotic) to the Krebs cycle carbon pool. We introduced a ’leakage term’ in
section ”Overestimation of secretion” covering all cataplerotic and anaplerotic contributions to
the Krebs cycle. However, using R1 and R2 and the equations in section ”Overestimation of
secretion” we can only calculate the total fraction of molecules extracted from the Krebs cycle,
d and not separate the citrate secretion from the other processes. Still we can assume c ≤ d.
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Figure 9: Relative 13C-NMR integrals of the six citrate carbons and carbon dioxide for different
values of fPC (A-C), with c = 0.3 and different values of c (D-F) with fPC = 0.2 after providing
[2,5-13C2]glucose or [2-
13C]pyruvate to prostate epithelial tissue or cells. Carbons C1 and C5,
and C2 and C4 have the same chemical shift and their integrals are therefore summed here.
Calculating d using R1:
R1 =
C2/4 − C3
C2/4
=
C2 + C4 − C3
C2 + C4
=
fPDC + 1−d1+df
PDC + fPC − 1−d1+dfPDC
fPDC + 1−d1+df
PDC + fPC
(54)
We can now again rewrite the expression to obtain fPDC as a function of d and R1:
fPDC =
1−R1
R1
1 + d
1− d (55)
From the [2,5-13C2]glucose or [2-
13C]pyruvate experiments we can calculate ratio R2:
R2 =
C1/5
C3
=
C1 + C5
C3
=
fPDC + 1−d2
(
1−d
1+df
PC + fPDC
)
2
1+df
PC
(56)
=
1−R1
R1
1+d
1−d +
1−d
2
(
1−d
1+d
(
1− 1−R1R1 1+d1−d
)
+ 1−R1R1
1+d
1−d
)
2
1+d
(
1− 1−R1R1 1+d1−d
) (57)
Substituting the experimentally found values for R1 and R2 we can now solve for d
(2−R1)d3 − (R1 + 2)d2 + (9R1 − 4R2 − 6)d+ (8R1R2 +R1 − 4R2 − 2) = 0 (58)
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Figure 10: Fraction pyruvate carboxylase fPC versus secretion probability c with lines repre-
senting different values for R1 and R2 plotted.
This means that the real secretion probability for citrate c should be smaller or equal to the
value found for d.
Fraction fPC vs fPDC with efflux of other metabolites
Now, using the expression we derived earlier we can calculate fraction fPDC (and at the same
time fPC):
fPDC =
1−R1
R1
1 + d
1− d
fPC =1− fPDC
(59)
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Figure 11: Confidence intervals for PC fraction and secretion probability c at different error
levels. Fraction pyruvate carboxylase fPC versus secretion probability c with values for pyru-
vate carboxylase fraction fPC = 0.1, fPC = 0.2 and fPC = 0.4, and values for the secretion
probability c = 0.3 and c = 0.7. Confidence intervals were calculated for an estimation error (or
noise level) of 1%, 2% and 5% of the biggest integral in the equations for R1 and R2 (From the
equations derived in sections ”Providing [1,6-13C2]glucose or [3-
13C]pyruvate to tissue/cells” and
”Providing [2,5-13C2]glucose or [2-
13C]pyruvate to tissue/cells” follows that C2/4 is the largest
integral for R1 and C1/5 for R2 for all physical values of c and f
PC).
So, still most of the 13C labels do enter the Krebs cycle via the fPDC route. Only a small part
of the 13C labels flow into the Krebs cycle via the anaplerotic pathway via pyruvate carboxylase.
The fact that we take leakage into account fortunately does not affect the values of fPC or fPDC .
Average number of Krebs cycle turns with efflux of other metabolites
Calculating the average number of completed cycle turns before secretion of citrate when leakage
is involved, can be calculated in a similar way for d as for c.
< n >=
n=∞∑
n=0
nd(1− d)n = 1− d
d
(60)
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Probability c versus d
It is not possible to distinguish c and d from each other in the experiments we described, but we
do know that the secretion probability c has to be smaller than d if there is carbon flowing out
of the Krebs cycle somewhere, so we can say that less than the calculated fraction d of citrate
molecules are secreted every cycle turn. The average number of completed cycle turns before
secretion of citrate, in the situation that there are no other processes involved, would be even
larger.
23
−−→ 13 C
d
is
tr
=
−→ C
(0
)
+
−→ C
(1
)
+
−→ C
(2
)
+
−→ C
(3
)
+
..
.
=
n
=
∞ ∑ n=0
−→ C
(n
)
−−→ 13 C
g
lc
-1
,6
d
is
tr
=
               
0
cf
P
D
C
0
f
P
C
0 0 0
               c
+
               
0
cf
P
D
C
c 2
f
P
D
C
c 2
f
P
D
C
1 2
f
P
C
1 2
f
P
C
0
               c(1
−
c)
+
               
0
cf
P
D
C
3
c 4
f
P
D
C
3
c 4
f
P
D
C
c 4
f
P
D
C
c 4
f
P
D
C
1 c
f
P
C
               c(1
−
c)
2
+
               
0
cf
P
D
C
7
c 8
f
P
D
C
7
c 8
f
P
D
C
3
c 8
f
P
D
C
3
c 8
f
P
D
C
1 2
f
P
D
C
               c(1
−
c)
3
+
..
.
=
                
0
f
P
D
C
1
−
c
1
+
c
f
P
D
C
1
−
c
1
+
c
f
P
D
C
+
f
f
P
C
1
−
c
2
( 1−c 1+c
f
P
D
C
+
f
P
C
)
1
−
c
2
( 1−c 1+c
f
P
D
C
+
f
P
C
)
(1
−
c
)2
c
( 1−c 1+c
f
P
D
C
+
f
P
C
)                c
−−→ 13 C
g
lc
-2
,5
d
is
tr
=
               cf
P
D
C
0
f
P
C
0 0 0 0
               c
+
               cf
P
D
C
0
1 2
f
P
C
1 2
f
P
C
c 2
f
P
D
C
c 2
f
P
D
C
0
               c(1
−
c)
+
               
cf
P
D
C
0
1 4
f
P
C
1 4
f
P
C
c 2
f
P
D
C
+
1 4
f
P
C
c 2
f
P
D
C
+
1 4
f
P
C
f
P
D
C
               c(1
−
c)
2
+
               
cf
P
D
C
0
1 8
f
P
C
1 8
f
P
C
c 2
f
P
D
C
+
1 8
f
P
C
c 2
f
P
D
C
+
1 8
f
P
C
f
P
D
C
+
1 2
c
f
P
C
               c(1
−
c)
3
+
..
.
=
                
f
P
D
C
0
2
1
+
c
f
P
C
1
−
c
1
+
c
f
P
C
1
−
c
2
( 1−c 1+c
f
P
C
+
f
P
D
C
)
1
−
c
2
( 1−c 1+c
f
P
C
+
f
P
D
C
)
(1
−
c
)2
c
( 1−c 1+c
f
P
C
+
f
P
D
C
)                c
T
ab
le
2:
1
3
C
d
is
tr
ib
u
ti
on
s
ov
er
si
x
ci
tr
at
e
ca
rb
o
n
s
a
n
d
ca
rb
o
n
d
io
x
id
e
fo
r
n
=
0
−
3
a
n
d
th
e
re
su
lt
o
f
su
m
m
a
ti
o
n
o
f
co
n
tr
ib
u
ti
o
n
s
o
f
al
l
K
re
b
s
cy
cl
e
tu
rn
s.
T
op
ro
w
is
af
te
r
p
ro
v
id
in
g
p
ro
st
a
te
ep
it
h
el
ia
l
ce
ll
s
o
r
ti
ss
u
e
w
it
h
[1
,6
-1
3
C
2
]g
lu
co
se
o
r
[3
-1
3
C
]p
y
ru
va
te
a
n
d
b
o
tt
o
m
ro
w
sh
ow
s
th
e
re
su
lt
af
te
r
p
ro
v
id
in
g
[2
,5
-1
3
C
2
]g
lu
co
se
o
r
[2
-1
3
C
]p
y
ru
va
te
.
Discussion & Conclusions
In this paper we derived a probabilistic model describing the production of citrate in the mito-
chondria of prostatic epithelial cells and secretion into the luminal space or incubation medium,
employing 13C labeling of secreted citrate as read-out. We were able to calculate the secretion
probability for citrate and calculate the contribution of pyruvate dehydrogenase complex (PDC)
versus the anaplerotic pyruvate carboxylase (PC) pathway in supplying the Krebs cycle with
carbons from pyruvate. We suggest two simple ratios of 13C NMR signal integrals that can
be obtained after supplementation with 13C labeled glucose or pyruvate to prostate tissue in
vivo or cell lines in vitro. This measure is shown to be independent of 13C-enrichment of the
administered supplements. Since the total NMR integrals of the citrate carbons are measured,
the model is independent of 13C J-coupling patterns, making this method more robust if SNR is
low. It can be adjusted for use with other 13C labeled supplements, especially if those are feed-
ing the acetyl-CoA pool. Next to this an estimation of pyruvate carboxylase (PC) contribution
and pyruvate dehydrogenase complex (PDC) contribution of carbon entering the Krebs cycle is
provided.
We assumed the 13C pyruvate pool to be large compared to the Krebs cycle 13C pool, which
results in an average constant flow of 13C labels flowing into the Krebs cycle over time. Another
assumption made in deriving this model is the constant secretion probability of citrate over time.
If the tissue or cells are provided with a constant flow of 13C label for a long period of time,
we assume that the epithelial cells are in a steady state with respect to citrate production and
general metabolism on average during this period.
After citrate diverges from the Krebs cycle and is transported to the cytosol it can be used in
de novo lipid sythesis and other metabolism. Assuming lipid synthesis and secretion of citrate
by the transporters out of the cells is constant over time this doesn’t influence the 13C labeling
pattern found for citrate in the extracellular fluid or incubation medium since an equal fraction
of all citrate present in the cytosol will be lost to lipid synthesis or other metabolism indepen-
dent of the 13C labeling of the citrate. Only if the 13C labels subsequently end up in the Krebs
cycle again this could influence the final outcome of the experiments, but we assume this to be
negligible.
Apart from secretion of citrate, we assumed no other efflux of metabolites during each cycle turn,
which makes the secretion probability described earlier an upper limit for citrate secretion. The
secretion probability calculated from experimental values using this model reflects on the total
fraction of molecules diverging from the Krebs cycle during one cycle turn, not only citrate. The
efflux of other metabolites is shown in section ”Overestimation of secretion” to not have an effect
on the value of fPC or fPDC but it does result in an overestimation of secretion probability c.
Efflux from the Krebs cycle pool can be due to for example conversion of α-ketoglutarate into
glutamate by glutamate dehydrogenase, pyruvate production from oxaloacetate via PEPCK and
aspartate transaminase activity. The latter is part of the malate-aspartate shuttle and catalyzes
the conversion of α-ketoglutarate into glutamate and of oxaloacetate into aspartate, and con-
tributes to the efflux of metabolites from the Krebs cycle for production of amino acids and
proteins. Multiple metabolic flux modeling studies have calculated total Krebs cycle fluxes and
net influx and efflux from the Krebs cycle. In some cases exchange fluxes were calculated in
addition to net fluxes. Especially interesting is the high exchange flux associated with the ex-
change between α-ketoglutarate and glutamate, comparable or even exceeding total Krebs cycle
fluxes in vivo in tissues like heart25,27 and brain24,28–30. But also in vitro in metastatic cell lines
like melanoma17,18, hepatocyte and hepatoma23 and glioma19 cells. Depending on the size of the
unlabeled glutamate pool this can result in a fast isotopical dilution of the α-ketoglutarate pool,
resulting in loss of 13C labeled carbon skeletons. This and the loss of 13C-labeled Krebs cycle
metabolites to other parts of metabolism accounts for the efflux of metabolites from the Krebs
cycle. Until now no literature values for similar exchange fluxes are available for prostate tissues
or cell systems. Future efforts can be made to extend the model with an estimation of loss of
13C labeled carbon skeletons to glutamate using intracellular glutamate pool size and (relative)
exchange fluxes. Other abundant metabolites diverging from the Krebs cycle should be identified
as well to better estimate the fraction of citrate secretion to the total loss of carbon skeletons
from the Krebs cycle. Including efflux of metabolites during a Krebs cycle turn would decrease
the estimated secretion probability for citrate. The average number of completed Krebs cycle
turns before secretion of citrate that is calculated depends on the total efflux of metabolites from
the cycle, not only on the secretion of citrate.
The high labeling efficiency of citrate using the 13C substrates described here make these sub-
strates ideal candidates for studying the unique secretion of citrate by prostate tissue. Still,
extending this model to other 13C labeled substrates or other isotopes like 14C or 2H could be
of interest in future studies.
We propose in this model an index for citrate production and secretion in prostatic tissue versus
Krebs cycle activity. A change in this index could indicate a shift in metabolism and could be
used to probe therapy effectiveness. For this it would be necessary to first measure a baseline
index in healthy prostate tissue by measuring citrate secreted by healthy epithelial tissue in vivo
and secondly determine how much the index changes upon malignancy or treatment.
Appendix
Average number of Krebs cycle turns for a 13C label
The average number of Krebs cycle turns a 13C carbon completes before ending up in either
citrate or carbon dioxide depends on the carbon position it starts out from at n = 0. For a 13C
carbon starting at citrate C2 or C3 the fraction of 13C carbon ending up in citrate or carbon
dioxide during Krebs cycle turn n is:
CCitr2/3 (n = 0) = c (61)
CCitr2/3 (n = 1) = c(1− c) (62)
CCitr2/3 (n ≥ 2) =
c(1− c)n
2n−2
(63)
And the fractions of 13C carbon ending up in carbon dioxide at cycle turn n is:
CCO22/3 (n = 0) = 0 (64)
CCO22/3 (n = 1) = 0 (65)
CCO22/3 (n ≥ 2) =
(1− c)n+1
2n−1
(66)
Multiplying this by the corresponding Krebs cycle turn index n and summing this over all possible
values of n gives us the average number of Krebs cycle turns a 13C carbon starting at C2 or C3
completes before ending up in citrate or carbon dioxide.
< nCitrC2/3 > =
n=∞∑
n=0
nCCitr2/3 (n) = c(1− c)
(
1 + 2
(1− c)(3 + c)
(1 + c)2
)
(67)
< nCO2C2/3 > =
n=∞∑
n=0
nCCO22/3 (n) =
(3 + c)(1− c)3
(1 + c)2
(68)
We can do the same for citrate C1 and C4, this results in:
CCitr1/4 (n = 0) = c (69)
CCitr1/4 (n = 1) = c(1− c) (70)
CCitr1/4 (n ≥ 2) = 0 (71)
And the following contributions for cycle turn n for carbon dioxide:
CCO21/4 (n = 0) = 0 (72)
CCO21/4 (n = 1) = (1− c)2 (73)
CCO21/4 (n ≥ 2) = 0 (74)
Again we can calculate the average number of cycle turns a 13C carbon starting at citrate C1 or
C4 completes before secretion in citrate or ending up in carbon dioxide.
< nCitrC1/4 > =
n=∞∑
n=0
nCCitr1/4 (n) = c(1− c) (75)
< nCO2C1/4 > =
n=∞∑
n=0
nCCO22/3 (n) = (1− c)2 (76)
Depending on the 13C substrate is used the 13C carbons in citrate start at different positions at
n = 0. For [1,6-13C2]glucose or [3-
13C]pyruvate 13C carbon ends up at C2 via the PDC route and
at C4 via the PC route. For [2,5-13C2]glucose or [2-
13C]pyruvate the 13C carbons start at citrate
C1 via PDC and at citrate C3 via PC. The result is that the true average number of Krebs cycle
turns a 13C carbon completes before ending up in citrate or carbon dioxide also depends on the
value of fPC . Calculating this for the [1,6-13C2]glucose or [3-
13C]pyruvate substrates:
< nCitrglc-1,6 > = f
PDC < nCitrC2/3 > +f
PC < nCitrC1/4 > (77)
= fPDCc(1− c)
(
1 + 2
(1− c)(3 + c)
(1 + c)2
)
+ fPCc(1− c) (78)
< nCO2glc-1,6 > = f
PDC < nCO2C2/3 > +f
PC < nCO2C1/4 > (79)
= fPDC
(3 + c)(1− c)3
(1 + c)2
+ fPC(1− c)2 (80)
And for the [2,5-13C2]glucose or [2-
13C]pyruvate substrate
< nCitrglc-1,6 > = f
PC < nCitrC2/3 > +f
PDC < nCitrC1/4 > (81)
= fPCc(1− c)
(
1 + 2
(1− c)(3 + c)
(1 + c)2
)
+ fPDCc(1− c) (82)
< nCO2glc-1,6 > = f
PC < nCO2C2/3 > +f
PDC < nCO2C1/4 > (83)
= fPC
(3 + c)(1− c)3
(1 + c)2
+ fPDC(1− c)2 (84)
This is plotted for fPC = 0.2 in Figure 12.
Figure 12: Average number of Krebs cycle turns a 13C carbon completes before being secreted
in citrate or being lost into carbon dioxide versus secretion probability c. The fraction pyruvate
carboxylase is set to fPC = 0.2 and the values at c = 0.3 are indicated with squares.
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